Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Additional Dosage of Edoxaban Filed in Japan for Elderly with High Bleeding Risk
September 14, 2020
- Nihon Chouzai’s Standard Formulary Service Expands to 17 Therapeutic Classes, Monitor Hospitals Moving to Craft Own Lists
September 11, 2020
- 1st Japanese COVID-19 Patient Enrolled in Global PIII of Ultomiris: Alexion
September 11, 2020
- Enspryng Reduces Risk and Severity of Relapse by 79% in NMOSD Patients: Chugai
September 11, 2020
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
- Hisamitsu Seeks Label Expansion for Fentos Tape to Pediatric Cancer Pain
September 11, 2020
- MSD Files Keytruda for MSI-H Colorectal Cancer
September 11, 2020
- RegeNephron, Kirin Join Hands on Cell Therapy Process Development
September 10, 2020
- Takeda to Divest Non-Core Products Sold in Europe, Canada to Cheplapharm
September 10, 2020
- Japan Ethical Drug Sales Down 4.9% in July: Crecon
September 9, 2020
- SymBio Setting Up Standalone Sales System for Treakisym in Japan
September 9, 2020
- Eisai Succeeds Parkinson’s Disease Med Equfina from Meiji Pharma on Sept. 23
September 8, 2020
- Keytruda Returns to Top Spot After 2 Months in August Sales Ranking: Encise
September 7, 2020
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat to Be Filed in US in Early 2021
September 7, 2020
- AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results
September 7, 2020
- Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
September 4, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Approved for Chronic Idiopathic Thrombocytopenic Purpura
September 4, 2020
- US Launch of Takeda’s Entyvio SC to Be Pushed Back to 2022
September 4, 2020
- Flawed Testing at Kyowa CritiCare Costs 2 More Product Recalls
September 4, 2020
- Aspen Japan Completes Takeover of Marketing Authorization, Distribution Rights for Lexotan
September 3, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…